United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.
The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.
Market Analysis and Insights: Global Induced Pluripotent Stem Cells (iPSCs) Market
The global Induced Pluripotent Stem Cells (iPSCs) market size is projected to reach US$ 203.6 million by 2027, from US$ 90 million in 2020, at a CAGR of 12.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Induced Pluripotent Stem Cells (iPSCs) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Induced Pluripotent Stem Cells (iPSCs) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Induced Pluripotent Stem Cells (iPSCs) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Induced Pluripotent Stem Cells (iPSCs) market.
Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Type
Human iPSCs had a market share of 89.65% in 2019, followed by Mouse iPSCs.
Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Application
Drug Development and Discovery
Academic Research is the largest segment of Induced Pluripotent Stem Cells (iPSCs) application,with a share of 32% in 2019.
Based on regional and country-level analysis, the Induced Pluripotent Stem Cells (iPSCs) market has been segmented as follows:
Rest of Europe
Rest of Asia-Pacific
Middle East & Africa
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Induced Pluripotent Stem Cells (iPSCs) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Fujifilm Holding Corporation (CDI)
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Cell Inspire Biotechnology